Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by u2bobon Mar 15, 2018 11:40am
111 Views
Post# 27720367

RE:RE:RE:RE:POSITIVE NEWS

RE:RE:RE:RE:POSITIVE NEWS
Willthethrill wrote: I really like the statement "As DIAGNOS continues to develop new algorithms and detect more illness." from the last NR. I think that as soon as the cardio is ready, Medicare will use it. And maybe Diagnos is planning to use this algorithm for allot more illnesses. I can see them using it to detect melanoma and other skin diseases as well.


The company looks to have a few things in the pipeline...the best part is they will run on CARA platform which is already FDA approved...I would think after showimg how well DR has worked...Cardio and others running on the same platform should give ADK a big advantage when it comes time to go from pipeline to market...my guess is one the big boys we wait till we get Cardio in place then takeover of ADK ...let the little guy do all the heavy lifting and approvals...imho...

 CARA is a proprietary teleophthalmology platform, which includes advance retinal imaging technology and clinical grading services. Developed inhouse, the platform is a software program that uses enhanced digital images to support and identify, at an early stage, vision loss, and more specifically, diabetic retinopathy. The company has received regulatory approvals from authorities such as US FDA “5 10 k”, Health Canada, and CE in Europe for CARA. It operates in 15 countries at different degrees of deployment, with installations in hospitals, clinics and mobile vans.  
 
In addition to CARA, which is in the production phase and remains the key sales contributor, the company has actively been developing other healthcare-focused software tools as well, which are in different phases of development. CARDIO is another important software being tested by DIAGNOS in four countries, after CARA, and appears to have strong growth potential. A few other healthcare-focused software tools, which are presently in the development phase, include OCT, Sleep Apnea and Alzheimer’s disease.     
 
Later...
Bob
Bullboard Posts